Society for Clinical Research Sites Experiences Extraordinary Response to Global Impact Partner Program; Pfizer, GSK, Quintiles,

  Society for Clinical Research Sites Experiences Extraordinary Response to
Global Impact Partner Program; Pfizer, GSK, Quintiles, and More to Join SCRS'
                          Commitment to Site Success

  PR Newswire

  ROCKVILLE, Maryland, Oct. 3, 2013

-- SCRS Global Impact Partner Program Welcomes: DrugDev, EMD Serono, Forte
Research Systems, GlaxoSmithKline, HealthCarePoint, IntegReview IRB, Janssen,
Merge Healthcare, Pfizer, Quintiles.

ROCKVILLE, Maryland, Oct. 3, 2013 /PRNewswire/ -- New organizations
representing sponsors, CROs, and clinical service providers continue to join
the SCRS' Global Impact Partner (GIP) program. SCRS will host the first GIP
Board meeting at the upcoming 2013 Site Solutions Summit. Since launching the
GIP program in June of this year, SCRS has welcomed more than 20 organizations
to join the society's commitment to global clinical research site success.
SCRS GIPs will provide ongoing support to the SCRS mission, and help to ensure
industry initiatives include the voice of clinical research sites.

The GIP Board will work in tandem with SCRS' Leadership Council to identify
the work streams most significant to ensure the success of the research sites
around the globe. Each GIP member has appointed one executive to represent
their organization while making a two year commitment to the GIP program. The
initial GIP work streams will be agreed upon and launched following this
year's Site Solutions Summit.

The new GIP industry members, EMD Serono, GlaxoSmithKline, Janssen, Pfizer,
and Quintiles will join founding partners Amgen, AstraZeneca, Eli Lilly, PPD,
and Roche.

New GIP professional partners include: Drug Dev, Forte Research Systems,
HealthCarePoint, IntegReview IRB, and Merge Healthcare will join founding
partners: Acurian, Aspire IRB, Clinical Conductor, CFS Clinical, Clinical Site
Services, DAC Patient Recruitment Services, and ePharmaSolutions.

SCRS President, Christine Pierre explains "Industry continues to respond
favorably to a unified community of sites, and the idea that sites should no
longer be the underrepresented partner in the clinical research process. Sites
represent a critical link between industry and patient, and have an incredible
stake in every step of clinical discovery. Having this unified voice will
provide process and operational efficiencies that will improve sustainability
for everyone involved in clinical research. Not only is SCRS now representing
sites in 22 countries, but within just 6 months of launching its GIP program,
to have more than 20 GIP partners is affirmation that these companies are
showing their commitment to the sites. SCRS looks forward to working with
current and future GIP partners to ensure all industry views are considered
towards strengthening the site community."

About SCRS

SCRS is a trade organization representing global clinical research sites
representing 1,300 sites in 22 countries in just a little less than a year of
its launch. SCRS' mission is to unify and amplify the voice of the global
clinical research site community. SCRS has become an active partner in
industry-wide dialogues focused on improving the clinical research enterprise
among the many industry initiatives. Sites, as well as companies that sponsor
or support the work conducted at the clinical research sites, will also
benefit from membership. Visit .

Contact: Denise Davis, Executive Coordinator, Society for Clinical Research
Sites, +1.410.696.5080,
Press spacebar to pause and continue. Press esc to stop.